Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival
Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years
Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer
ASCO and CAP Issue Guideline To Improve HER2 Testing
Phase III Ramucirumab Trial Fails Primary Endpoint of PFS
Kadcyla Extends Median PFS In Open-Label Phase III Trial
Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease
Colon Polyps in Elderly Patients Are More Likely to Be Found Only with Colonoscopy
Phase III Vaccine Trial Fails To Improve Overall Survival
Central Line Safety Intervention Lowers Patient Infection Rate
Phase II Study Shows Positive Results in Reducing Dry Mouth
NCI CTEP Approved Trials For the Month of October
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- White House announces “TrumpRx,” a new prescription drug website
- The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.” - Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?
